How Cosentyx Controls Psoriasis Symptoms
Cosentyx (secukinumab) targets IL-17A, reducing plaque buildup, scaling, and redness in moderate-to-severe plaque psoriasis. Patients continuing treatment maintain clear or almost clear skin in 70-80% of cases after 52 weeks, compared to rapid relapse upon stopping.[1][2]
Long-Term Joint Relief in Psoriatic Arthritis and Ankylosing Spondylitis
For psoriatic arthritis, ongoing use prevents joint damage progression, with 80-84% achieving low disease activity at 2 years. In ankylosing spondylitis, it sustains reduced spinal inflammation and pain, improving BASDAI scores by over 50% long-term.[1][3]
Benefits for Other Conditions Like Hidradenitis Suppurativa
Continuous dosing clears inflammatory nodules and abscesses, with 45-50% response rates at week 16 extending to 75% remission by week 52 in moderate-to-severe cases.[1]
Why Stopping Leads to Flare-Ups
Discontinuation often causes symptom rebound within 12-20 weeks—psoriasis PASI scores double, and arthritis flares return in 60-70% of patients—making sustained treatment key for remission.[2][4]
Safety Profile During Long-Term Use
Year 5 data show low serious infection risk (2-3 per 100 patient-years), no increased malignancy, and stable efficacy without new safety signals in over 20,000 patients.[1][5]
[1]: Novartis Cosentyx Prescribing Information
[2]: JAAD: Secukinumab Long-Term Efficacy in Psoriasis
[3]: Annals of Rheumatic Diseases: Secukinumab in PsA
[4]: Lancet: Withdrawal Effects in IL-17 Inhibitors
[5]: EULAR 2023: Cosentyx 5-Year Safety Data